Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?

Annals of Surgery

Volumn 257, Issue 6, 2013, Pages 1065-1071

  Goéré, Diane ^a   Malka, David ^a   Tzanis, Dimitri ^a   Gava, Vinicius ^a   Boige, Valérie ^a   Eveno, Clarisse ^a   Maggiori, Léon ^a   Dumont, Frédéric ^a   Ducreux, Michel ^a   Elias, Dominique ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Colorectal cancer; Hyperthermic intraperitoneal chemotherapy; Peritoneal carcinomatosis; Surgery

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; CARCINOMATOSIS; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM CANCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURGICAL MORTALITY;

ADULT; AGED; CARCINOMA; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PERITONEAL NEOPLASMS; PROGNOSIS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84879095854     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31827e9289     Document Type: Article

References (48)

1. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-1550.
2. Rosen SA, Buell JF, Yohida A, et al. Initial presentationwith stage IVcolorectal cancer. Arch Surg. 2000;135:503-505.
3. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364-367.
4. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from nongynecologic malignancies: results of EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-363.
5. Verwaal VJ, Van Ruth S, De Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-3743.
6. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047.
7. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
8. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer. NEngl JMed. 2009;360:1408-1417.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
10. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
11. Elias D, Lefèvre J, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681-685.
12. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900-907.
13. Tomlinson JS, Jarnagin WR, De Matteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575-4580.
14. Pulitanò C, Castillo F, Aldrighetti L, et al. What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up. HPB (Oxford). 2010;12:244-249.
15. Viganò L, Ferrero A, Lo Tesoriere R, et al. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-termsurvivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. 2008;15:2458-2464.
16. Chua TC, Saxena A, Chu F, et al. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5-and 10-year survivors. J Surg Oncol. 2011;103:796-800.
17. Adam R, Wicherts DA, De Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829-1835.
18. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
19. Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267-272.
20. Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004;15:1558-1565.
21. Clavien PA, Barkun J, De Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187-196.
22. Dy GK, Hobday TJ, Nelson G, et al. Long-termsurvivors ofmetastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer. 2009;8:88-93.
23. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721-5727.
24. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. J Clin Oncol. 2012;30:263-267. doi:10.1200/JCO.2011.38.8199
25. Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756-3762.
26. Klaver YL, Lemmens VE, Creemers GJ, et al. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22:2250-2256.
27. Chua TC, Morris DL, Saxena A, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 2011;18:1560-1567.
28. Manfredi S, Lepage C, Hatem C. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254-259.
29. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649-655.
30. Adam R, Pascal G, Castaing D, et al. Tumor progressionwhile on chemotherapy a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052-1064.
31. Pelz JO, Doerfer J, Dimmler A, et al. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006;6:162.
32. Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol. 2010;2:19-30.
33. Elias D, Glehen O, Pocard M, et al. Acomparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel and nonpseudomyxoma appendix. Ann Surg. 2010;251:896-901.
34. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63-68.
35. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284-3292.
36. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011-4019.
37. Elias D, Blot F, El Otmany A. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71-76.
38. Da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203:878-886.
39. Archer A, Sugarbaker PH, Jelinel JS. Radiology of peritoneal carcinomatosis. Cancer Treat Res. 1996;82:263-288.
40. De Bree E, Koops W, Kr̈oger R, et al. Peritoneal carcinomatosis from colorectal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol. 2004;86:64-73.
41. Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging. 2008;33:87-93.
42. Low RN. Extrahepatic abdominal imaging in patients with malignancy: comparison of MR imaging and helical CT in 164 patients. J Magn Reson Imaging. 2000;12:269-277.
43. Elias D, Góeŕe D, Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2008;247:445-450.
44. Ito H, Are C, Gonen M, et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:994-1002.
45. Laurent C, Sa Cunha A, Couderc P, et al. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90:1131-1136.
46. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg. 2004;240:644-657.
47. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420-425.
48. Góeŕe D, Deshaies I, De Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251:686-691.